The study authors call for greater caution in using antibiotics for travellers' diarrhoea, except in severe cases, as part of broader efforts to fight the growing public health crisis of antibiotic resistance and the spread of highly resistant bacteria worldwide.
"The great majority of all cases of travellers' diarrhoea are mild and resolve on their own," said lead study author Anu Kantele, associate professor in infectious diseases at Helsinki University Hospital in Finland.
Their goal was to determine if their guts became colonised by a resistant type of bacteria from the Enterobacteriaceae family that produces a key enzyme, extended-spectrum beta-lactamase (ESBL), which confers resistance to many commonly used antibiotics.
The researchers looked for risk factors in the travellers' behaviour that may have facilitated colonisation by these resistant bacteria.
The US Centres for Disease Control and Prevention has called ESBL-producing bacteria a serious concern and a significant threat to public health.
The bacteria can cause severe infections that are harder and more expensive to treat and more likely to be fatal.
Overall, 21 per cent of the travellers to tropical and subtropical areas in the study had unknowingly contracted ESBL-producing bacteria during their trips.
Significant risk factors for colonisation were travellers' diarrhoea and treating it with antibiotics while abroad. Among those who took antibiotics for diarrhoea, 37 per cent were colonised, researchers said.
Those travelling to South Asia faced the highest risk of contracting the resistant bacteria: 80 per cent of travellers who took antibiotics for diarrhoea while visiting the region were colonised with ESBL bacteria.
Even if colonised travellers do not develop infections themselves, they may, after returning home, unknowingly spread the superbugs to their own developed countries, where today these bacteria are less prevalent, researchers said.
The study was published in Clinical Infectious Diseases.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
